Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 18/20 | 0.65 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.42 |
| ▸ | CSNK1D | P48730 | 1/20 | 0.39 |
| ▸ | CSNK1E | P49674 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6284207 | 0.83 | MAPK14 (0.69) | MAPK14PTGS2CSNK1DCSNK1E | |
| SCHEMBL6280887 | 0.79 | MAPK14 (1.00) | MAPK14PTGS2 | |
| SCHEMBL3889529 | 0.78 | MAPK14 (0.69) | MAPK14PTGS2CSNK1DCSNK1E | |
| SCHEMBL6601604 | 0.77 | MAPK14 (0.61) | MAPK14CSNK1DCSNK1E | |
| SCHEMBL11464007 | 0.75 | MAPK14 (0.56) | MAPK14PTGS2MEN1ALDH1A1LMNA | |
| SCHEMBL6505328 | 0.74 | MAPK14 (0.51) | MAPK14PTGS2MEN1ALDH1A1LMNA | |
| SCHEMBL30242346 | 0.73 | MAPK14 (1.00) | MAPK14CSNK1DCSNK1EMAPK1 | |
| SCHEMBL6280916 | 0.73 | MAPK14 (0.67) | MAPK14CSNK1DCSNK1EMEN1ALDH1A1 | |
| SCHEMBL6285603 | 0.73 | MAPK14 (0.50) | MAPK14PTGS2MEN1ALDH1A1LMNA | |
| SCHEMBL6508320 | 0.72 | MAPK14 (0.55) | MAPK14PTGS2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050080113-A1 | Medicinal compositions | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2005-04-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050080113-A1 | Medicinal compositions | TNF, TRAF6, MMP8 | MAPK14 50/4885PTGS2 57/4885CSNK1D 982/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.